FDA Enforcement and the Gray Market: What's Happening in 2026

The FDA enforcement wave against gray-market peptide vendors has accelerated dramatically since late 2024. What began as a handful of warning letters has expanded into a coordinated campaign involving criminal prosecutions by the Department of Justice, warehouse raids, more than fifty warning letters to compounding pharmacies, and over a hundred trademark lawsuits from pharmaceutical manufacturers. The message from federal regulators is no longer ambiguous: selling injectable peptides outside the regulated pharmaceutical system carries real legal consequences.

Criminal charges are now on the table. The DOJ has prosecuted at least two major peptide vendors, with guilty pleas secured in both cases.
The FDA is using its full enforcement toolkit — warning letters, recalls, inspections, and coordinated action with the DOJ.
The GLP-1 market explosion has drawn political and regulatory attention to the entire compounding and gray-market peptide space.
Quality failures in independent testing provide the FDA with clear public-safety justification for aggressive enforcement.

Quick facts

Criminal prosecutions: 2+ (DOJ)
FDA warning letters: 50+ (September 2025)
Novo Nordisk lawsuits: 130+ filed
Major vendor shutdowns: 3+
Estimated market impact: $billions

A timeline of enforcement

The enforcement pattern has followed a clear escalation — from civil letters to criminal prosecution to physical raids. Here are the key actions, in chronological order.

Late 2024 — Tailor Made Compounding (DOJ criminal prosecution). The Department of Justice charged the owners of Tailor Made Compounding, a large-scale compounder based in Texas, with distributing unapproved new drugs. The case resulted in a guilty plea and $1.79 million in asset forfeiture.^[1] This was one of the first criminal prosecutions — not just a warning letter — targeting the peptide supply chain directly.

December 2025 — Paradigm Peptides (DOJ criminal prosecution). Paradigm Peptides, one of the most visible gray-market peptide vendors in the United States, saw its operators enter guilty pleas in federal court.^[2] The prosecution focused on the sale of injectable peptides to individual consumers under "research use only" labels — a framing the government rejected outright.

June 2025 — Amino Asylum (FDA warehouse raid). FDA agents reportedly raided the warehouse of Amino Asylum, another prominent gray-market vendor. The company's website went offline and has remained offline since. No public criminal charges have been announced as of this writing, but the raid itself signals an active investigation.

September 2025 — 50+ FDA warning letters to GLP-1 compounders. In a single coordinated action, the FDA issued more than fifty warning letters to compounding pharmacies producing semaglutide and tirzepatide products.^[3] The letters cited quality violations, lack of registered API sourcing, and distribution of unapproved drugs. This was the largest single batch of enforcement letters targeting the peptide and compounding space.

2024–2026 — 130+ Novo Nordisk lawsuits. Novo Nordisk, the manufacturer of Ozempic and Wegovy, filed more than 130 lawsuits against compounding pharmacies and raw material suppliers producing compounded semaglutide.^[4] These combined trademark infringement, patent claims, and FDCA violations. While these are civil cases rather than government enforcement, they have effectively shut down numerous compounders and created significant legal risk across the supply chain.

March 6, 2026 — Peptide Sciences shutdown. Peptide Sciences, which retailer analytics firm Grips Intelligence estimated was generating roughly $7.45 million per month in revenue,^[9] displayed a shutdown notice on its website and ceased accepting orders. Independent testing by Finnrick Analytics had previously given the company an E rating (lowest possible) for its retatrutide product across 37 samples.^[6] For a detailed analysis, see our coverage of the Peptide Sciences shutdown.

The "research use only" defense is dead

For years, gray-market peptide vendors operated under a legal theory: if they labeled products "for research use only" or "not for human consumption," they were selling research chemicals rather than drugs, and therefore fell outside FDA jurisdiction.

The FDA has dismantled this argument. Under federal law, the agency evaluates intended use based on the totality of evidence — not just what the label says.^[7] When a company sells injectable peptides alongside bacteriostatic water, includes dosing calculators on its website, markets to individual consumers rather than research institutions, and ships to residential addresses, the FDA considers these unapproved drugs regardless of any disclaimer.

In the Paradigm Peptides prosecution, prosecutors specifically cited the "research use only" label as a "ruse" designed to evade regulatory oversight.^[2] The guilty pleas that followed confirmed that courts agree.

This matters because the research-use-only model was the legal foundation on which the entire gray-market peptide industry was built. With that foundation gone, every remaining vendor operating under the same model faces the same legal exposure.

The quality problem underneath

Enforcement actions do not happen in a vacuum. The FDA's justification for aggressive action rests in part on documented quality failures in the gray-market supply chain — failures that create genuine public safety risks.

Independent testing data paints a stark picture:

43% of gray-market peptides failed to meet their label purity claims in 2024 Janoshik Analytical testing.^[5]
23% of retatrutide samples contained exendin-4 analogs — a completely different molecule — rather than actual retatrutide.^[5]
Endotoxin contamination has been detected in a measurable percentage of gray-market samples by Finnrick Analytics.^[6]
Quantity discrepancies up to 48% from the advertised amount have been documented across 5,930 tested samples from 196 vendors.^[6]

These are not theoretical risks. When nearly one in four samples of a specific peptide contains the wrong molecule, and when nearly half of all tested products fail purity claims, the FDA has a straightforward public safety argument for shutting vendors down.

For consumers trying to evaluate product quality, understanding how to read a Certificate of Analysis is a critical skill. Our COA verification guide walks through the process step by step, and our COA checker tool can help you evaluate a COA for red flags.

What's driving the crackdown

Several forces have converged to produce this enforcement wave.

The GLP-1 market explosion. The success of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) created a multi-billion-dollar market virtually overnight. When compounding pharmacies and gray-market vendors began selling cheaper alternatives, the economic stakes became large enough to attract serious regulatory and legal attention.^[8]

Political pressure. Consumer safety incidents — including hospitalizations from contaminated compounded injectables — have generated congressional inquiries and media scrutiny. The FDA faces pressure to demonstrate it is protecting consumers from unsafe products.

Pharmaceutical industry lobbying. Companies like Novo Nordisk have invested heavily in both litigation and lobbying to protect their branded products from compounded competition. The 130+ lawsuits represent a private-sector enforcement effort that parallels and reinforces the government's actions.^[4]

Documented safety failures. Every quality failure that surfaces in independent testing or adverse event reports strengthens the FDA's position. The 43% purity failure rate, the wrong-molecule findings, the endotoxin contamination — these provide concrete, defensible reasons for enforcement rather than abstract regulatory theory.

The combination of these factors means the current enforcement wave is not a temporary crackdown that will ease once attention moves elsewhere. The structural incentives — economic, political, and safety-related — all point in the same direction.

What this means for you

If you have been sourcing peptides from gray-market vendors, here is a clear-eyed assessment of where things stand.

Don't panic. The peptides you already have don't change because a vendor shut down or a prosecution was announced. If you've been using a product without adverse effects, nothing about the enforcement landscape changes your immediate situation.

Understand the trend. The gray-market model for peptide sales is contracting. Vendors are shutting down, being prosecuted, or facing lawsuits. The remaining vendors operate under the same legal exposure as those that have already been taken down. This is not a temporary dip — it is a structural shift.

Shift toward legitimate channels. Compounding pharmacies that operate under USP standards and source FDA-registered APIs provide a fundamentally different level of quality assurance. With a valid prescription from a licensed provider, many peptides can be legally compounded today. Telehealth platforms have made this accessible nationwide.

Stay informed. The regulatory landscape is changing rapidly. HHS Secretary Kennedy's February 2026 announcement that approximately 14 peptides could be reclassified from Category 2 to Category 1 would expand legal compounding access significantly — but formal FDA action has not yet been published. We will continue tracking enforcement actions, reclassification developments, and access pathways as they evolve.

References

[1]
U.S. Department of Justice. “Tailor Made Compounding LLC owner pleads guilty to federal drug charges, forfeits $1.79 million.” 2024. Link
DOJ press release documenting criminal prosecution of a major compounding pharmacy for distributing unapproved drugs. Includes $1.79M forfeiture and guilty plea.
[2]
U.S. Department of Justice. “Paradigm Peptides operators plead guilty to distributing unapproved new drugs.” 2025. Link
DOJ prosecution of a prominent gray-market peptide vendor. Guilty pleas entered December 2025.
[3]
U.S. Food and Drug Administration. “Warning letters to compounding firms regarding GLP-1 receptor agonist products.” 2025. Link
FDA issued 50+ warning letters to GLP-1 compounders in September 2025 for quality violations and distributing unapproved drugs.
[4]
Novo Nordisk A/S. “Litigation against compounders of semaglutide products — aggregate case filings.” 2025. Link
Novo Nordisk filed 130+ lawsuits against compounding pharmacies and suppliers selling compounded versions of semaglutide. Combination of trademark, patent, and FDCA claims.
[5]
Janoshik Analytical. “Public peptide testing database — 2024 aggregate results.” 2024. Link
Independent analytical testing laboratory (Prague). Not ISO 17025 accredited, but widely used in the research peptide community with a substantial public track record.
[6]
Finnrick Analytics. “Peptide vendor testing database — 5,930 samples from 196 vendors.” 2025. Link
US-based independent testing service (Texas). Offers free peptide testing. Maintains public vendor rating database.
[7]
U.S. Food and Drug Administration. “Guidance for industry: intended use and adequate directions for use.” 2025. Link
FDA guidance explaining that intended use is determined by the totality of evidence — including packaging, labeling, marketing, and context of sale — not solely by label disclaimers.
[8]
U.S. Food and Drug Administration. “FDA's concerns with unapproved GLP-1 drugs used for weight loss.” 2025. Link
FDA safety communication documenting adverse events from compounded semaglutide and tirzepatide, including dosing errors requiring hospitalization.
[9]
Grips Intelligence. “Peptide Sciences retailer traffic and transaction estimates.” 2026. Link
Third-party retailer analytics platform providing estimated revenue and transaction data for e-commerce brands.

The regulatory landscape is moving fast

Get notified when new regulatory changes affect peptide access. We track the FDA, so you don't have to.

News

What Happened to Peptide Sciences

A detailed look at the largest gray-market vendor shutdown.

Guide

How to Verify a Certificate of Analysis

Learn to evaluate peptide quality documentation.

Tool

COA Checker

Evaluate a Certificate of Analysis for red flags.

Peptide

BPC-157

The most popular gray-market research peptide. Full evidence profile and regulatory status.